Relapsed refractory multiple myeloma with CNS involvement successfully treated with Elranatamab: first reported case.

Mutlu, Yasa Gul; Yigit Kaya, Sureyya; Maral, Senem; Melek, Elif; Baslar, Zafer; Kaynar, Leylagul; Sevindik, Omur Gokmen

Mutlu, Yasa Gul; Yigit Kaya, Sureyya; Maral, Senem; Melek, Elif; Baslar, Zafer; Kaynar, Leylagul; Sevindik, Omur Gokmen.

Affiliation

Mutlu YG; Department of Hematology, Istanbul Medipol University, Istanbul, Türkiye.
Yigit Kaya S; Department of Hematology, Istanbul Medipol University, Istanbul, Türkiye.
Maral S; Department of Hematology, Istanbul Medipol University, Istanbul, Türkiye.
Melek E; Department of Hematology, Istanbul Medipol University, Istanbul, Türkiye.
Baslar Z; Department of Hematology, Istanbul University-Cerrahpasa, Istanbul, Türkiye.
Kaynar L; Department of Hematology, Istanbul Medipol University, Istanbul, Türkiye.
Sevindik OG; Department of Hematology, Istanbul Medipol University, Istanbul, Türkiye.

Front Immunol ; 14: 1276295, 2023.

Article de En | MEDLINE | ID: mdl-37901215

Sujet(s)
Mots clés

BCMA; CNS involvement; Elranatamab; bispecific Ab; multiple myeloma

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Anticorps bispécifiques / Myélome multiple Limites: Adult / Humans / Male Langue: En Journal: Front Immunol Année: 2023 Type de document: Article

Texte intégral

Ajouter à My VHL

Imprimer

XML

PubMed Links

Recherche sur Google